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Background
Effective health policy requires a thorough understanding
of intrinsic social, ethical, political and philosophical
aspects of infertility and its treatment. The procedure with
the highest success rate to address the clinical challenge
of infertility for many patients is a relatively high-tech-
nology procedure, in vitro fertilisation (IVF).
Introduction
More than half of all reported IVF cycles undertaken
worldwide occur in Europe [1], yet there is considerable
diversity in European public funding strategies for treating
infertility [2]. Prevailing reimbursement guidelines have
been developed to assuage safety and regulatory concerns,
although economic factors are also important. In the con-
text of public policy debate, arguments to restrict public
funding for IVF are generally supported by the observa-
tion that treatment should be preferentially provided to
younger women [3] because published data has shown that
the effectiveness of IVF declines with female age >40yrs
[4,5]. This stance seeks to exclude older women who are
more likely to have a greater need for IVF [2]. Policy
decisions involving the growth of family are important;
any eligibility criteria must be supported by studies with-
out methodological limitations in order to capture the
broadest possible cost/benefit analysis of IVF. It has
recently been recognised that the available fiscal data on
the economics of IVF is indeed limited, and should be
augmented by more robust evidence to guide policy mak-
ers in the development of particular social reimbursement
schemes [2]. Accordingly, this paper introduces the fol-
lowing body of new research based on a comprehensive
investigation on the monetary, regulatory and policy fac-
tors that drive the cost of IVF.
In subsequent issues, The Journal of Experimental &
Clinical Assisted Reproduction (JECAR) presents results
from detailed investigations on IVF gathered in the U.K.
by Dr. Christopher Jones and colleagues. These studies
represent definitive evaluations of the cost-effectiveness
of IVF, designed for a wide readership— practitioners,
medical consumers and policy makers. With an emphasis
on various embryo transfer policies, the authors present
IVF protocols grouped by cost-effectiveness for specified
clinical populations. Against a background of clinical IVF
practice in the U.K. National Health Service (NHS), def-
initions and descriptions of all relevant terms are provided.
The authors also provide a computational analysis of a
generic IVF cycle, including a synopsis of key personnel
involved in daily clinic operation. This enables an objec-
tive calculation of relative contributions of manpower and
supplies consumed in a typical IVF cycle. Based on U.K.
data derived from the Human Fertilisation & Embryology
Authority (HFEA), an incremental cost-effectiveness
analysis estimates extra costs for an additional livebirth
event, showing how additional embryos transferred may
be cost-effective for certain patient populations.
Recognising the significance of multiple gestation fol-
lowing IVF, this team explores health care cost models
based on data from neonatal intensive care and special care
baby units; length of stay (LOS) as a function of plurality
and gestational age at delivery is also investigated. Few
previous studies account for these indirect costs of IVF,
and therefore may result in an underestimation of the total
socioeconomic impact of IVF [6]. Jones and colleagues
relate LOS across male vs. female singletons, twins and
triplets. The economics of rare reproductive outcomes,
including multiple birth following single embryo transfer,
are also considered.
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From civilisation’s earliest beginnings, the stigma of
infertility has been a recognised cultural phenomenon.
How best to use limited health care resources to confront
this challenge in modern times remains controversial, in
part due to a paucity of economic data [7]. IVF is now
regarded as a safe and effective remedy to infertility for
many couples [8]. Providing a fresh perspective on a
familiar problem, the forthcoming papers by Jones and
colleagues address this difficult issue from the U.K. per-
spective. The recognised need for a thorough and robust
economic assessment of IVF is, in large measure,
addressed by the investigative efforts of Jones and collea-
gues. In developing their cost/benefit analysis of such a
heavily-regulated clinical intervention like IVF in the
U.K., the authors have acknowledged that the need to
focus on individual patients and/or providers is eclipsed
by the need to deal with the underlying policy frameworks
that guide them. Evidence is provided to show how U.K.
government policy has already been modified in response
to these data. It is hoped that further studies in other juris-
dictions will lead to better informed policy debates else-
where, and JECAR welcomes an opportunity to consider
those reports for potential publication when available.
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